-
公开(公告)号:US20170356917A1
公开(公告)日:2017-12-14
申请号:US15524186
申请日:2015-10-20
IPC分类号: G01N33/574 , G01N33/573 , C12Q1/48
CPC分类号: G01N33/57426 , C12Q1/485 , G01N33/573 , G01N2333/912
摘要: The invention provides, inter alia, methods of prognosing the survival of a multiple myeloma patient based levels of TP53RK in multiple myeloma cells of the patient. Also provided are methods of screening for therapeutic agents for treating multiple myeloma based on their ability to decrease TP53RK levels or activity in a patient with multiple myeloma.
-
公开(公告)号:US20160272579A1
公开(公告)日:2016-09-22
申请号:US15034276
申请日:2014-11-05
IPC分类号: C07C237/40 , A61K31/69 , C07D213/82 , A61K31/4406 , A61K31/167 , C07D239/42 , A61K31/505 , C07D241/24 , A61K31/4965 , A61K45/06 , C07D213/81
CPC分类号: C07C237/40 , A61K31/167 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/455 , A61K31/4965 , A61K31/505 , A61K31/69 , A61K38/05 , A61K45/06 , C07C237/42 , C07D213/81 , C07D213/82 , C07D239/42 , C07D241/24 , A61K2300/00
摘要: The present invention relates to compounds which inhibit histone deacetylase activity and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing these compounds. The present invention also relates to methods of treating and preventing hematological cell proliferative disorders, such as multiple myeloma, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
摘要翻译: 本发明涉及抑制组蛋白脱乙酰酶活性的化合物和合成这些化合物的方法。 本发明还涉及含有这些化合物的药物组合物。 本发明还涉及通过将这些化合物和药物组合物给予有需要的受试者来治疗和预防血液细胞增殖性疾病如多发性骨髓瘤的方法。
-
公开(公告)号:US20230271966A1
公开(公告)日:2023-08-31
申请号:US18013106
申请日:2021-06-28
发明人: Kenneth C. Anderson , Teru Hideshima , Sirano Dhe-Paganon , Hyuk-Soo Seo , Takashi Mizutani , Tinghu Zhang
IPC分类号: C07D487/04 , C07D401/04 , C07D413/14 , A61P35/00
CPC分类号: C07D487/04 , C07D401/04 , C07D413/14 , A61P35/00
摘要: This disclosure relates to compounds of formula (I) as defined in the Specification. This disclosure also relates to methods of synthesizing the compound of formula (I) and using the compounds of formula (I) for treating a disease (e.g., cancer).
-
公开(公告)号:US20200331889A1
公开(公告)日:2020-10-22
申请号:US16769059
申请日:2018-12-13
IPC分类号: C07D401/14
摘要: The application relates to a compound of Formula (I) which modulate the amount of STK4, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease or disorder associated with the modulation of STK4.
-
公开(公告)号:US10172905B1
公开(公告)日:2019-01-08
申请号:US15401902
申请日:2017-01-09
发明人: Kenneth C. Anderson , James E. Bradner , Edward Franklin Greenberg , Teru Hideshima , Nicholas Paul Kwiatkowski , Ralph Mazitschek , Stuart L. Schreiber , Jared Shaw , Stephen J. Haggarty
IPC分类号: A61K38/05 , A61K31/4965 , A61K31/69 , A61K45/06 , A61K49/00 , G01N33/50 , A61K31/422 , A61K38/50 , A61K31/35 , A61K31/357
摘要: The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.
-
公开(公告)号:US20150191417A1
公开(公告)日:2015-07-09
申请号:US14413745
申请日:2013-07-10
申请人: Dana-Farber Cancer Institute, Inc. , The General Hospital Corporation d/b/a Massachusettls General Hospital
IPC分类号: C07C223/06 , C07D233/80 , C07C251/48 , C07C251/86 , C07D211/62
CPC分类号: C07C223/06 , A61K31/136 , A61K31/15 , A61K31/164 , A61K31/165 , A61K31/216 , A61K31/395 , A61K31/4166 , A61K31/445 , A61K31/655 , A61K31/69 , A61K45/06 , C07C251/48 , C07C251/86 , C07D211/62 , C07D233/80 , A61K2300/00
摘要: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, tautomers, stereoisomers, solvates, hydrates, polymorphs, and compositions thereof. Also provided are methods and kits involving the inventive compounds for treating proliferative diseases (e.g., cancers (e.g., breast cancer, prostate cancer, lung cancer, and ovarian cancer), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound of the invention may enhance the anti-tumor immune response by inhibiting or eliminating the immune suppression mediated by immune suppressor myeloid cells (MDSCs), inducing apoptosis, and/or inhibit or down-regulate proteins (e.g., epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), X-linked inhibitor of apoptosis protein (XIAP), and heat shock protein 90 (Hsp90)) in the subject.
摘要翻译: 本发明提供新的式(I)化合物及其药学上可接受的盐,互变异构体,立体异构体,溶剂合物,水合物,多晶型物及其组合物。 还提供了涉及用于治疗受试者的增殖性疾病(例如,癌症(例如,乳腺癌,前列腺癌,肺癌和卵巢癌),良性肿瘤,血管发生,炎性疾病和自身免疫性疾病)的本发明化合物的方法和试剂盒 。 使用本发明化合物治疗患有增殖性疾病的受试者可通过抑制或消除由免疫抑制骨髓细胞(MDSC)介导的免疫抑制,诱导凋亡和/或抑制或下调 蛋白质(例如表皮生长因子受体(EGFR),人表皮生长因子受体2(HER2),雌激素受体(ER),X连锁蛋白抑制剂(XIAP)和热休克蛋白90(Hsp90)) 学科。
-
公开(公告)号:US20240124459A9
公开(公告)日:2024-04-18
申请号:US18013106
申请日:2021-06-28
发明人: Kenneth C. Anderson , Teru Hideshima , Sirano Dhe-Paganon , Hyuk-Soo Seo , Takashi Mizutani , Tinghu Zhang
IPC分类号: C07D487/04 , A61P35/00 , C07D401/04 , C07D413/14
CPC分类号: C07D487/04 , A61P35/00 , C07D401/04 , C07D413/14
摘要: This disclosure relates to compounds of formula (I) as defined in the Specification. This disclosure also relates to methods of synthesizing the compound of formula (I) and using the compounds of formula (I) for treating a disease (e.g., cancer).
-
公开(公告)号:USRE49240E1
公开(公告)日:2022-10-11
申请号:US16815755
申请日:2020-03-11
IPC分类号: C07C237/40 , A61K31/167 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/455 , A61K31/4965 , A61K31/505 , A61K31/69 , A61K38/05 , A61K45/06 , C07C237/42 , C07D213/81 , C07D213/82 , C07D239/42 , C07D241/24
摘要: The present invention relates to compounds which inhibit histone deacetylase activity and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing these compounds. The present invention also relates to methods of treating and preventing hematological cell proliferative disorders, such as multiple myeloma, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
-
公开(公告)号:US10302644B2
公开(公告)日:2019-05-28
申请号:US15524186
申请日:2015-10-20
IPC分类号: C12N15/113 , C12N15/11 , G01N33/574 , C12Q1/48 , G01N33/573
摘要: The invention provides, inter alia, methods of prognosing the survival of a multiple myeloma patient based levels of TP53RK in multiple myeloma cells of the patient. Also provided are methods of screening for therapeutic agents for treating multiple myeloma based on their ability to decrease TP53RK levels or activity in a patient with multiple myeloma.
-
公开(公告)号:US09988343B2
公开(公告)日:2018-06-05
申请号:US15034276
申请日:2014-11-05
IPC分类号: A61K31/4406 , A61K31/167 , A61K31/69 , C07C237/40 , C07D213/82 , C07D241/24 , A61K38/05 , A61K45/06 , A61K31/4402 , A61K31/4409 , A61K31/455 , A61K31/4965 , A61K31/505 , C07D213/81 , C07D239/42 , C07C237/42
CPC分类号: C07C237/40 , A61K31/167 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/455 , A61K31/4965 , A61K31/505 , A61K31/69 , A61K38/05 , A61K45/06 , C07C237/42 , C07D213/81 , C07D213/82 , C07D239/42 , C07D241/24 , A61K2300/00
摘要: The present invention relates to compounds which inhibit histone deacetylase activity and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing these compounds. The present invention also relates to methods of treating and preventing hematological cell proliferative disorders, such as multiple myeloma, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
-
-
-
-
-
-
-
-
-